Overview: Adagene Inc. is a clinical stage biotechnology company focused on the research, development, and production of monoclonal antibody drugs for cancer treatment, with a market cap of ...

About Adagene Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer ...

Adagene has a 52-week low of $1.33 and a 52-week high of $3.58. Institutional Investors Weigh In On Adagene Several hedge funds have recently made changes to their positions in the company.

The Company is pursuing strategic partnerships to advance the SAFEbody T cell engager programs. Exelixis: In June 2023, Adagene received a US$3.0 million milestone payment from Exelixis for the ...

Adagene Inc. announced positive clinical results from its Phase 2 dose expansion study of muzastotug (ADG126) in patients with microsatellite stable colorectal cancer, reporting a 33% overall ...

Adagene Inc. announced its participation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025, where it will present its clinical program for ADG126, a novel anti-CTLA-4 ...

For deeper insights into Adagene's financial health and 12+ additional ProTips, visit InvestingPro. The stock has experienced significant volatility, with a year-to-date return of -7.54% and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment ...

As the United States market navigates a period of volatility amid tariff announcements and economic uncertainties, investors are keenly observing opportunities that may arise in less conventional ...